Patient safety

Elston, Dirk M.; Taylor, James S.; Coldiron, Brett M.; Hood, Antoinette F.; Read, Sandra I.; Resneck, Jack S.; Kirsner, Robert S.; Maize, John C.; Sullivan, Sabra; Laskas, John J.; Hanke, C. William

doi:10.1016/j.jaad.2009.04.056

Cited by 21 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If an adverse effect occurs, the practitioner should decide on the next treatment step with the patient's best interest and safety in mind. The severity of the underlying disease, degree of risk from the adverse effect, other treatment options and risks related to abrupt discontinuation of the medication should all be taken into account when making this judgment (Elston, Stratman, et al, 2009;Elston, Taylor, et al, 2009;Wolverton, 2013).…”

Section: Managementmentioning

confidence: 99%

Challenges and strategies in dermatologic therapy—Personalized medicine, patient safety, and pharmacoeconomics

Šitum

Franceschi

2019

Dermatologic Therapy

View full text Add to dashboard Cite

Skin conditions are among the most prevalent and disabling diseases affecting millions of people worldwide. Recently, there have been significant changes in dermatologic clinical practice. Advances in knowledge of disease pathophysiology have led to significant breakthroughs in diagnostics and therapy, as well as discovery of new treatment modalities. Additionally, research focusing on differences between individual patients has resulted in the growth of personalized medicine. Health care professionals are focusing on tailoring therapy to the individual characteristics of each patient, which in turn leads to improved quality of care and management of each individual. Of note, patient safety may be compromised when applying or taking dermatologic therapy as a result of medical error, patient noncompliance, adverse effects, or drug interactions. It is therefore of great importance to minimize, and if possible prevent these risks. Finally, the appraisal of health care goods and services currently does not only analyze the safety and efficacy of treatment, but also considers the economic impact on the cost of health care. Consequently, pharmacoeconomic evaluation has become an essential step in the introduction of new dermatologic treatments and the rational use of pharmaceuticals.

show abstract

Section: Managementmentioning

confidence: 99%

Challenges and strategies in dermatologic therapy—Personalized medicine, patient safety, and pharmacoeconomics

Šitum

Franceschi

2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…4 Thus, the American Academy of Dermatology has emphasized the importance of reducing WSS. 5 A study by Nijhawan and colleagues found that 25% of patients receiving Mohs surgery at a private single cancer center could not identify their biopsy location because the duration between biopsy and surgery allowed biopsy sites to heal well, which made finding the lesion difficult. 6 Risk factors for WSS include having multiple health care providers (HCPs) living remote from the surgery location involved in the case, being a traveling veteran, receiving care at multiple facilities inside and outside the US Department of Veterans Affairs (VA) system, mislabeling photographs or specimens, and pho-tographs not taken at time of biopsy and too close with no frame of reference to assist in finding the correct site.…”

mentioning

confidence: 99%